Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

Abstract Background NEPA is an oral fixed-dose combination of netupitant, a new highly selective neurokinin-1 receptor antagonist, and palonosetron. This study was conducted to evaluate whether the efficacy of NEPA against chemotherapy-induced nausea and vomiting (CINV) in cycle 1 would be maintaine...

Full description

Bibliographic Details
Main Authors: Roberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, Rosalba Torrisi, Ida Paris, Monica Giordano, Vincenzo Montesarchio, Valentina Guarneri, Laura Amaducci, Domenico Bilancia, Giuseppina Cilenti, Alessandra Fabi, Elena Collovà, Alessio Schirone, Erminio Bonizzoni, Luigi Celio, Sabino De Placido, Michelino De Laurentiis
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
NEPA
CINV
Nausea
Vomiting
Breast cancer
AC
Online Access:http://link.springer.com/article/10.1186/s12885-020-6707-9

Internet

http://link.springer.com/article/10.1186/s12885-020-6707-9

Similar Items